Article ; Online: Effects of gender affirming hormone therapy with testosterone on coagulation and hematological parameters in transgender people assigned female at birth: A systematic review and meta-analysis.
2024 Volume 236, Page(s) 170–178
Abstract: Background: Hormone replacement therapy is associated with an increased thromboembolic risk. The effects of testosterone (T) on coagulation markers in people assigned female at birth (AFAB) under gender affirming hormone therapy (GAHT) are not well ... ...
Abstract | Background: Hormone replacement therapy is associated with an increased thromboembolic risk. The effects of testosterone (T) on coagulation markers in people assigned female at birth (AFAB) under gender affirming hormone therapy (GAHT) are not well described. Methods: Systematic review and meta-analysis on English-language articles retrieved from PubMed, Scopus and Cochrane Library up to April 2023 investigating T therapy in AFAB people. Coagulation parameters included international normalized ratio (INR), fibrinogen, activated partial thromboplastin clotting time (aPTT), plasminogen activator inhibitor-1 (PAI-1); hematological variables included hemoglobin (Hb) and hematocrit (HCT). We also reported the rate of thromboembolic events. Data were combined as mean differences (MD) with a 95 % confidence interval (CI) of pre- vs post-follow-up values, using random-effects models. Results: We included 7 studies (6 prospective and 1 retrospective) providing information on 312 subjects (mean age: 23 to 30 years) who underwent GAHT with variable T preparation. T therapy was associated with a significant increase in INR values [MD: 0.02, 95 % confidence interval (CI): 0.01-0.03; p = 0.0001], with negligible heterogeneity (I Conclusion: Therapy with T increased blood viscosity in AFAB men. A slight increase in INR values was also found, but the clinical relevance and mechanism(s) of this finding needs to be clarified. |
---|---|
MeSH term(s) | Adult ; Female ; Humans ; Male ; Young Adult ; Fibrinogen/analysis ; Plasminogen Activator Inhibitor 1 ; Prospective Studies ; Retrospective Studies ; Testosterone/adverse effects ; Thromboembolism ; Transgender Persons |
Chemical Substances | Fibrinogen (9001-32-5) ; Plasminogen Activator Inhibitor 1 ; Testosterone (3XMK78S47O) |
Language | English |
Publishing date | 2024-03-04 |
Publishing country | United States |
Document type | Meta-Analysis ; Systematic Review ; Journal Article |
ZDB-ID | 121852-9 |
ISSN | 1879-2472 ; 0049-3848 |
ISSN (online) | 1879-2472 |
ISSN | 0049-3848 |
DOI | 10.1016/j.thromres.2024.02.029 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 863: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.